Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pacira BioSciences, Inc. (NASDAQ: PCRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Pacira is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its filings give detailed insight into how it manages product commercialization, manufacturing, financing and governance.
Pacira’s current reports on Form 8‑K cover topics such as quarterly financial results, workforce reductions tied to manufacturing efficiencies for EXPAREL, and a senior secured revolving credit facility used to refinance prior indebtedness and support working capital. One 8‑K describes the company’s investment in large-scale manufacturing suites in San Diego, California, and Swindon, United Kingdom, and the decision to decommission an earlier 45‑liter batch suite, while another outlines the terms of its credit agreement with lenders.
Investors reviewing Pacira’s filings typically focus on annual reports on Form 10‑K and quarterly reports on Form 10‑Q for information about its commercial products—EXPAREL, ZILRETTA and iovera°—and its clinical-stage gene therapy candidate PCRX-201. These filings generally discuss revenue composition, research and development activities, manufacturing capacity, risk factors and intellectual property, including patent protection for EXPAREL described in company press releases.
Forms 8‑K also document material events such as share repurchase authorizations, inducement equity grants under the company’s inducement plan, credit facility amendments and other significant corporate actions. For users interested in insider activity, Forms 3, 4 and 5 provide data on transactions by directors, officers and major shareholders, while proxy statements explain executive compensation and board matters.
On Stock Titan, AI-generated summaries help explain lengthy filings, highlight key changes from prior periods and surface items that may affect Pacira’s financial position or strategy. Real-time updates from EDGAR ensure that new 10‑K, 10‑Q, 8‑K and Form 4 filings for PCRX are quickly available, allowing investors to track developments in Pacira’s non-opioid pain portfolio, manufacturing initiatives and capital structure without reading every page manually.
Pacira BioSciences Chief Financial Officer Shawn Cross was granted 49,091 restricted stock units of common stock on February 11, 2026. The award was reported at a price of
The restricted stock units vest in four equal annual installments beginning on
Pacira BioSciences Chief Administrative Officer Kristen Williams received an equity award of 54,546 shares of common stock on February 11, 2026. The award is in the form of restricted stock units granted at a price of $0 per share, described as a grant, award, or other acquisition.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as she remains in continuous service with the company on each vesting date. Each unit represents the right to receive one share of Pacira common stock. Following this grant, Williams beneficially owns 185,849 shares of Pacira common stock directly.
Pacira BioSciences, Inc. reported an equity award to Chief Commercial Officer Brendan Teehan. On February 11, 2026, he acquired 51,714 shares of common stock at a price of $0 under a grant classified as an award or other acquisition.
The award represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, as long as he remains in continuous service with the company on each vesting date. After this grant, Teehan directly beneficially owns 100,934.268 shares of Pacira common stock.
RIKER LAUREN reported acquisition or exercise transactions in a Form 4 filing for PCRX. The filing lists transactions totaling 19,273 shares. Following the reported transactions, holdings were 71,586 shares.
SLONIN JONATHAN reported acquisition or exercise transactions in this Form 4 filing.
Pacira BioSciences, Inc. reported that Chief Medical Officer Jonathan Slonin received an equity award of 54,546 shares of common stock on February 11, 2026. The award was granted at a price of $0 per share and is structured as restricted stock units.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as Slonin remains in continuous service with the company on each vesting date. After this grant, he beneficially owns 226,901.175 shares of Pacira common stock directly.
Pacira BioSciences, Inc. reported an equity award to its Chief Executive Officer and director, Frank D. Lee. On February 11, 2026, he acquired 261,818 shares of common stock in the form of restricted stock units granted at a price of $0 per share.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as he remains in continuous service with the company on each vesting date. Following this grant, Lee beneficially owns 660,830.841 shares of Pacira common stock directly.
Pacira BioSciences, Inc. Senior Vice President of Finance Lauren Riker reported routine equity transactions in company stock. On January 30, 2026, 2,751 shares of common stock were withheld by Pacira to cover tax obligations upon vesting of a restricted stock unit award at $20.54 per share. On February 2, 2026, Riker sold 4,000 shares of common stock at a weighted average price of $20.81 per share, executed under a pre-established Rule 10b5-1 trading plan. After these transactions, Riker directly beneficially owned about 52,313.242 shares of Pacira common stock.
Pacira BioSciences Chief Administrative Officer Kristen Williams reported two stock transactions. On January 30, 2026, 17,134 shares of common stock were withheld by Pacira to cover tax obligations upon vesting of a restricted stock unit award at a price of $20.54 per share, leaving her with 144,440 shares held directly.
On February 2, 2026, she sold 13,137 Pacira common shares at $20.53 per share in a transaction carried out under a pre-established Rule 10b5-1 trading plan. After this sale, she directly held 131,303 Pacira shares.
Pacira BioSciences Chief Medical Officer reports tax-share withholding. Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc., reported a Form 4 transaction involving company common stock. On 01/30/2026, 6,168 shares of common stock were withheld by Pacira to cover tax obligations when a restricted stock unit award vested at a price of $20.54 per share.
After this withholding, Slonin directly beneficially owned 172,355.175 shares of Pacira common stock. The transaction reflects tax-related share withholding rather than an open-market sale.
Pacira BioSciences, Inc. reported a routine insider tax-withholding transaction by its Chief Commercial Officer, Brendan Teehan. On 01/30/2026, 5,182 shares of common stock were withheld by the company at $20.54 per share to cover tax obligations upon vesting of a restricted stock unit award. After this withholding, Teehan directly beneficially owned 49,220.268 shares of Pacira common stock.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
